NLRP3 and cancer: Its downstream product, IL-18, can increase the cytotoxicity of NK cells, suggesting that NLRP3 inflammatory bodies have anti-cancer effects, and IL-1β and IL-18 have also been proven to inhibit anti-metastasis and immune surveillance mediated by NK cells and T cells to promote the occurrence and development of cancer (10).